Safety and efficacy of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open-label trial by Seyger, M.M.B. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2021-11-02 and may be subject to
change.
ORIGINAL ARTICLE
Safety and efficacy of fixed-dose combination
calcipotriol (50 lg/g) and betamethasone dipropionate
(0.5 mg/g) cutaneous foam in adolescent patients (aged 12
to <17 years) with plaque psoriasis: results of a phase II,
open-label trial
M. Seyger,1,* W. Abramovits,2 M. Liljedahl,3 M.N. Hoejen,4 J. Teng5
1Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands
2Dermatology Treatment & Research Centre, Dallas, TX, USA
3Medical Department, LEO Pharma A/S, Ballerup, Denmark
4Biostatistics, LEO Pharma A/S, Ballerup, Denmark
5Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA
*Correspondence: M. Seyger. E-mail: Marieke.Seyger@radboudumc.nl
Abstract
Background Fixed-dose combination of calcipotriol (50 lg/g; Cal) and betamethasone dipropionate (0.5 mg/g; BD)
foam is approved for plaque psoriasis treatment in adults, with a paucity of data supporting use in adolescents.
Objectives To evaluate safety of 4 weeks’ treatment with Cal/BD foam in adolescent patients with psoriasis, and
additional safety outcomes in patients with more severe disease (HPA-axis cohort). Primary objectives included treat-
ment-emergent adverse events (TEAEs) and systemic calcium levels in the overall population, and HPA-axis function,
change in calcium excretion and the calcium:creatinine ratio in the HPA-axis cohort. Secondary objectives included
exploratory efficacy endpoints [treatment success: change in Psoriasis Area and Severity Index (PASI)]. Systemic
exposure to Cal/BD was also assessed.
Methods A phase II, open-label, study (NCT02387853) in patients (12 to <17 years) with at least mild psoriasis, to eval-
uate Cal/BD foam applied once daily for ≤4 weeks.
Results In patients assigned to treatment (n = 106), 32 TEAEs occurred in 22 patients (20.8%). All but two
TEAEs were mild; none led to study withdrawal or death. Changes (0–4 weeks) in albumin-corrected serum cal-
cium (overall population) and urinary calcium excretion (HPA-axis cohort) were small, transient and not considered
clinically relevant. In the HPA-axis cohort, no change in urinary calcium:creatinine ratio was observed and
responses to adrenocorticotropic–hormone (ACTH) challenge did not suggest disruption of the HPA-axis.
Prespecified treatment success on the body and scalp was achieved by 71.8% and 75.7% of the overall popula-
tion, respectively. Mean PASI decreased by 82.0% vs. baseline at Week 4. Systemic exposure to Cal/BD was
minimal.
Conclusions Cal/BD foam was well tolerated in adolescent patients with body/scalp psoriasis. There was no evidence
for dysregulation of the HPA-axis nor calcium homoeostasis in patients with more severe disease. Exploratory efficacy
data in the overall population were encouraging.
Received: 19 August 2019; Accepted: 7 January 2020
Conflicts of interest
M. Seyger has received grants for consultancy and travel expenses from LEO Pharma, paid to her institution, and has
received grants and other fees for research, lecturing, consultancy and travel expenses from AbbVie, Lilly and Pfizer, and
grants for research, lecturing and consultancy from Janssen. W. Abramovits has received honoraria or fees for serving
on advisory boards as a speaker and as a consultant, and has received grants as an investigator from AbbVie, Akros,
Allergan, Amgen, Anacor Pharm, Aqua Pharma, Celgene, Centocor, Conversant Bio, Dermavant, Eli Lilly, Exeltis, Gal-
derma, Genentech, Glenmark, GSK, Innocutis, Innovaderm, Janssen Biotech, LEO Pharma, MediMetriks, Merck, Novar-
tis, Novan, Novum, Otsuka, Parexel, PharmaDerm, Perrigo, Pfizer, Premier, Promius, Prothena, PuraCap, Quinnova,
Ranbaxy, Regeneron, Rho, Sanofi, Serono, Taro, Teva, Tioga, Theorem, Tolmar, UCB, Valeant and Xenoport. M. Liljedahl
and M. Hoejen are employees of LEO Pharma. J. Teng has no relevant conflicts of interest to disclose.
© 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology
JEADV 2020, 34, 2026–2034
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
DOI: 10.1111/jdv.16233 JEADV
Funding source
The study was funded by LEO Pharma A/S. LEO Pharma A/S supported the study concept and design.
Introduction
Population-based studies estimate the prevalence of psoriasis in
children and adolescents at 0%–2%,1 increasing linearly between
the ages of 1 and 18 years.2 Age of onset is thought to be bimo-
dal, with the first peak between 15 and 20 years and the second
between 55 and 60 years.3
Topical, fixed-dose combination of calcipotriol (50 lg/g; as
monohydrate; Cal) and betamethasone (0.5 mg/g; as dipropi-
onate; BD) foam is currently approved in the United States and
EU for the treatment of plaque psoriasis in adults.4,5
The safety profile of Cal/BD foam has not previously been
established in adolescents with psoriasis. On the basis of clinical
evidence, the overall risk of TEAEs with Cal, a vitamin D ana-
logue, is low,6 and the current trial was designed to investigate
specific safety concerns of interest.
In addition to site-reaction concerns, systemic absorption of
calcium has been noted with long-term topical exposure to Cal,7
and a potential risk of hypercalcaemia has been highlighted.8–10
Lastly, hypothalamic–pituitary–adrenal (HPA) axis suppres-
sion has been noted with long-term use of corticosteroids7,11;
thus, HPA-axis dysregulation with BD is a concern. The adreno-
corticotropic–hormone (ACTH) challenge is used to assess
HPA-axis suppression in children with psoriasis,12 with a serum
cortisol value ≤18 lg/dL at 30 min post-ACTH challenge sug-
gestive of potential adrenal-cortisol insufficiency.13,14
After 4 weeks’ fixed-dose combination of Cal/BD foam,
we report safety outcomes in adolescents (12 to <17 years)
with plaque psoriasis of the body and scalp (including end-
points to assess calcium homoeostasis), and HPA-axis testing
(ACTH challenge) in those with more severe disease.




A phase II, multicentre, prospective, open-label, non-controlled,
single-group, 4-week trial in adolescent patients (aged 12 to
<17 years) with plaque psoriasis on the body and scalp
(NCT02387853) consisting of three periods: wash-out, treatment
and follow-up (Fig. 1). The study was a postapproval regulatory
commitment, with the design mandated by the US Food and
Drug Administration (FDA).
Standard protocol approvals, registration and patient
consents
The study was conducted in accordance with the principles of
the Declaration of Helsinki, and the clinical trial protocol (and
amendments) was approved by, or received favourable opinion
from, the relevant institutional review boards or independent
ethics committees. Informed written consent was obtained from
all patients and their parents (or legal guardians).
Patients
Patients were screened at 26 centres in the Netherlands, Poland,
Romania and the USA. All those enrolled were to be included in
the overall population, while a subset (approximately 30%) with
more severe disease were to be part of a maximal-use group, the
‘HPA-axis cohort’ (details below).
In the overall population, patients were 12 to <17 years and
had plaque psoriasis on the trunk and/or limbs, affecting ≥2% of
body surface area (BSA), and on the scalp, affecting ≥10% of
scalp surface area (SSA). Each patient’s total plaque psoriasis on
the trunk, limbs and scalp was ≤30% of BSA. Additional inclu-
sion criteria included physician’s global assessment (PGA) of
disease (clear, almost clear, mild, moderate, severe; according to
Feldman & Krueger 200515) of at least mild for body and scalp at
baseline, and albumin-corrected serum calcium below the upper
reference limit at baseline.
Exclusion criteria included systemic treatments that could
affect the body and/or scalp psoriasis within 4 weeks prior to the
first screening visit (except for adalimumab/infliximab and
ustekinumab, which patients must not have taken within 2 and
4 months prior, respectively); photochemotherapy within
4 weeks; UVB therapy within 2 weeks; topical treatment on the
body/scalp within 2 weeks; and systemic calcium and vitamin D
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Figure 1 Study design. *Patients were only required to attend
FU1 if they had an ongoing serious adverse event; any ongoing
adverse event considered possibly/probably related to study
treatment; or an albumin-corrected serum calcium value above the
reference range. Only patients in the HPA-axis cohort who had
≤18 lg/dL at 30 min post-ACTH challenge at Week 4 were
required to attend FU2. ACTH, postadrenocorticotropic–hormone;
FU1, follow-up visit 1; FU2; follow-up visit 2; HPA, hypothalamic–
pituitary–adrenal; SV1, screening visit 1; SV2, screening visit 2.
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In the HPA-axis cohort, patients were required to have more
severe disease: plaque psoriasis on the trunk and/or limbs affect-
ing ≥10% of BSA, plaque psoriasis on the scalp affecting ≥20%
of SSA and a PGA score of at least moderate for both body and
scalp at baseline. These patients were also required to have nor-
mal adrenal function at baseline, measured by post-ACTH chal-
lenge test (described previously16,17). Patients in the overall
population set but not in the HPA-axis cohort will henceforth
be referred to as the ‘non-HPA cohort’.
Study treatments
Cans containing 30 g of Cal/BD foam were provided. Patients
were instructed to apply treatment once daily, and continue
treating affected areas with Cal/BD foam throughout the 4-week
treatment period [the non-HPA cohort were allowed to discon-
tinue treatment (but required to remain in-trial) if lesions were
cleared at Week 2 (W2)].
The non-HPA cohort had the maximum dose per week lim-
ited (determined by patient age and BSA at baseline):
• Patients aged 12 to <15 years
o BSA of ≤1.3 m2: maximum 60 g per week.
o BSA of >1.3 m2: maximum 90 g per week.
• Patients aged ≥15 to <17 years
o BSA of ≤1.7 m2: maximum 90 g per week.
o BSA of >1.7 m2: maximum 120 g per week.
The HPA-axis cohort was treated under maximal-use condi-
tions (weekly dose was not limited).
Study visits took place on Day 0, W2 and Week 4 (W4), and
final assessments were carried out 2 weeks after end of treatment
(Fig. 1).
Objectives
Primary objectives were evaluation of the safety of once-daily
Cal/BD foam in adolescent patients with plaque psoriasis on the
body and scalp; and, in the HPA-axis cohort: assessment of
HPA-axis function post-ACTH challenge, change in calcium
excretion and the calcium:creatinine ratio. Secondary objectives
included assessment of exploratory efficacy endpoints after up to
4 weeks of treatment in the overall population and the HPA-axis
cohort.
Endpoints
Primary endpoints were treatment-emergent adverse events
(TEAEs) and change in albumin-corrected serum calcium
from baseline to W4. TEAEs were followed up until an out-
come was determined, and once a patient left the trial, events
classified as ‘possibly’ or ‘probably’ related to Cal/BD foam
were followed up for 14  2 days, or until an outcome was
determined. For the HPA-axis cohort, additional primary end-
points included number of patients with serum cortisol con-
centration ≤18 lg/dL at 30 min post-ACTH challenge at W4;
change in calcium excretion from baseline to W4 in 24-h
urine; and change in calcium:creatinine ratio from baseline to
W4 in 24-h urine.
Secondary endpoints included efficacy according to PGA
(treatment success defined as clear/almost clear for patients with
moderate psoriasis, and clear for those with mild), and treatment
success according to patient’s global assessment (PaGA) of dis-
ease severity (defined as clear or very mild) at W4 for the body
and scalp; percentage change in PASI15 from baseline to W4; and
change in itch (assessed by visual analogue scale) from baseline
to W4. For the HPA-axis cohort, the number of patients with
serum cortisol concentration ≤18 lg/dL at both 30 and 60 min
post-ACTH challenge at W4 was also a secondary endpoint.
Pharmacokinetics (PK) for the HPA-axis cohort and treat-
ment adherence in the overall population were also assessed. PK
was measured preapplication at W2, prior to ACTH challenge
and Cal/BD application at W4, and at 1, 3 and 5 h postapplica-
tion at W4.
Statistical methods
The safety analysis set (SAS), which included all patients except
those who received no treatment and/or provided no postbase-
line safety evaluations, was used to analyse adverse events and
change in albumin-corrected serum calcium from baseline to
W4. The per-protocol analysis set included all patients in the
HPA-axis cohort who received treatment, provided ACTH chal-
lenge test results at Week 4 and met the normal-adrenal-func-
tion-at-baseline inclusion criterion. The full analysis set (FAS)
included all patients assigned to treatment and was used for effi-
cacy analyses.
The trial was planned to be conducted in 100 evaluable adoles-
cent patients, with a subset of 30 patients forming the HPA-axis
cohort. This population size was deemed necessary to achieve an
86.7% probability that a true (theoretical) AE would be observed
in at least one patient, with an AE frequency of ≥2%.
Observed data have been presented with 95% confidence
intervals (CI). A post hoc analysis of efficacy endpoints (treat-
ment success by PGA; treatment success by PaGA; change in
PASI; change in itch) for the FAS and the HPA-axis and non-
HPA subgroups has also been presented.
Results
Patients
Overall, 117 patients were screened and 106 (non-HPA cohort,
n = 72; HPA-axis cohort, n = 34) were assigned to treatment
and constituted both the FAS and SAS (Fig. 2). During the treat-
ment period, three patients (one HPA-axis and two non-HPA)
withdrew from the study after Week 0 (no reason provided).
The first patient screening visit took place on 23 March
2016; the final patient follow-up visit was 28 March 2018.
Patient demographics and baseline disease characteristics are
© 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology
JEADV 2020, 34, 2026–2034
2028 Seyger et al.
summarized in Table 1. No noteworthy differences between the
HPA-axis and non-HPA cohorts were observed, excluding those
parameters in which differences were expected due to the HPA-
axis cohort inclusion criteria.
Compliance and posology
Over the 4 weeks of treatment, 101 patients (95.3%) reported
that they missed no applications of Cal/BD, 33 of whom were in
the HPA-axis cohort (i.e. 100% compliance for completers in
this cohort). One patient in the non-HPA cohort reported they
had missed more than half of their treatments, while one and
three patients (also in the non-HPA cohort) reported missing
>10% to ≤20% and ≤10% of treatment applications, respectively.
The mean weekly amount of Cal/BD foam used over the full
treatment period was 47.0 g [standard deviation (SD) 22.2] and
35.8 g (SD 28.0) for the HPA-axis and non-HPA cohorts,
respectively.
Safety
Adverse events Thirty-two TEAEs were reported by 22
patients (20.8%), and all but two TEAEs were of mild severity
(two moderate: erythema and myopia). The most frequent
TEAEs were upper respiratory tract infection [8 (7.5%)
patients], nasopharyngitis [4 (3.8%) patients] and acne [2
(1.9%) patients]; all other TEAEs were not reported by more
than one patient (Table 2). Six AEs reported by five patients
were assessed by the investigator as related to Cal/BD treat-
ment, with five considered possibly or probably related (acne,
erythema, skin reaction, application site pain and product
physical consistency issue) and one (myopia) deemed ‘un-
known’; therefore, for this AE, a relationship with Cal/BD
foam could not be ruled out. No deaths, serious TEAEs or
severe TEAEs were reported, and no TEAE led to study with-
drawal.
Local reactions (≤2 cm from the border of lesions treated with
Cal/BD) were few. The most frequently reported were dryness
and erythema, with 6.8% (n = 7) and 3.9% (n = 4) of patients
presenting with these local reactions at W2 and W4, respectively
(Fig. 3). Local reactions also appeared to improve over time. At
W4, no moderate reactions were reported and fewer patients
had mild reactions than at baseline.
Calcium metabolism In the overall population, mean change
in albumin-corrected serum calcium from baseline to W4 was
0.016 mmol/L (SD 0.119). Based on absolute values vs. the
reference range, six patients shifted from low to normal levels
of albumin-corrected serum calcium from baseline to W4,
while nine patients shifted from normal to low (Table 3). In
the HPA-axis cohort, the mean change in calcium excretion
in 24-h urine from baseline to W4 was –0.335 mmol/24 h
(SD 2.076) and three patients shifted from low to normal
levels, while nine shifted from normal to low (Table 3). None
of these changes were considered clinically relevant. In the
Patients enrolled into 
the non-HPA cohort, 
n = 72




Patients screened for 
the non-HPA cohort,
n = 83
Patients screened for 
the HPA-axis cohort,
n = 34
Patients enrolled into 
the HPA-axis cohort, 
n = 34
Patients in the HPA-axis cohort 
completed treatment,
n = 33
• Patient withdrew from the 
study, n = 1
(no reason provided)
• Patients withdrew from the 
study, n = 2
(no reason provided)
• Patients did not meet study 
eligibility criteria, n = 8 
• Patients withdrew from the 
study, n = 3
Figure 2 Patient disposition. Note that the per-protocol and non-per-protocol sets, used for reporting in Table 1, correspond to the
HPA-axis and non-HPA cohorts, respectively, with the exception of one patient in the HPA-axis cohort who withdrew after the baseline
visit, and are therefore included in the non-per-protocol set. HPA, hypothalamic–pituitary–adrenal.
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HPA-axis cohort, all patients had normal calcium:creatinine
ratios at baseline and W4; no shifts were observed (Table 3).
ACTH challenge test Of the 33 patients who underwent the
ACTH challenge test at W4, three individuals [9.1%; two evalu-
able and one who did not meet HPA-axis cohort enrolment cri-
teria (see details below)] had serum cortisol concentrations
≤18 lg/dL at 30 min post-ACTH challenge (17.6, 16.5, 15.0 lg/
dL, respectively). Of the two evaluable patients, serum cortisol
normalized (>18 lg/dL) at 60 min post-ACTH challenge. In
one of these patients, a second ACTH challenge was carried out
during a follow-up visit 2 weeks after completing treatment and
serum cortisol levels were normal at both 30 and 60 min
postchallenge. In the third patient, in whom the serum cortisol
Table 1 Patient demographics and baseline disease characteristics






Age, mean (SD), years 14.2 (1.4) 14.2 (1.3) 14.1 (1.4)
Sex, n (%)
Male 45 (42.5) 17 (51.5) 28 (38.4)
Female 61 (57.5) 16 (48.5) 45 (61.6)
Race, n (%)
White 102 (96.2) 33 (100.0) 69 (94.5)
Native Hawaiian or other Pacific Islander 1 (0.9) 0 (0.0) 1 (1.4)
Other 3 (2.8) 0 (0.0) 3 (4.1)
Fitzpatrick skin type, n (%)
I 5 (4.7) 1 (3.0) 4 (5.5)
II 44 (41.5) 12 (36.4) 32 (43.8)
III 46 (43.4) 16 (48.5) 30 (41.1)
IV 10 (9.4) 4 (12.1) 6 (8.2)
V 1 (0.9) 0 (0.0) 1 (1.4)
Duration of psoriasis, mean (SD), years 4.3 (2.9) 3.5 (2.4) 4.7 (3.1)
PGA of psoriasis on the body, n (%)
Mild 23 (21.7) 0 (0.0) 23 (31.5)
Moderate 81 (76.4) 33 (100.0) 48 (65.8)
Severe 2 (1.9) 0 (0.0) 2 (2.7)
PGA of psoriasis on the scalp, n (%)
Mild 15 (14.2) 0 (0.0) 15 (20.5)
Moderate 77 (72.6) 33 (100.0) 44 (60.3)
Severe 14 (13.2) 0 (0.0) 14 (19.2)
Patient’s global assessment of psoriasis on the body, n (%)
Very mild 2 (1.9) 0 (0.0) 2 (2.7)
Mild 23 (21.7) 1 (3.0) 22 (30.1)
Moderate 70 (66.0) 32 (97.0) 38 (52.1)
Severe 11 (10.4) 0 (0.0) 11 (15.1)
Patient’s global assessment of psoriasis on the scalp, n (%)
Very mild 3 (2.8) 0 (0.0) 3 (4.1)
Mild 10 (9.4) 1 (3.0) 9 (12.3)
Moderate 67 (63.2) 28 (84.8) 39 (53.4)
Severe 26 (24.5) 4 (12.1) 22 (30.1)
Extent of BSA involvement, mean (SD), %
Body 10.4 (7.1) 16.3 (3.4) 7.8 (6.7)
Scalp 50.6 (25.0) 55.5 (18.8) 48.4 (27.1)
Total 13.2 (7.5) 18.5 (3.4) 10.8 (7.6)
PASI, mean (SD) 8.6 (4.0) 10.5 (2.5) 7.7 (4.2)
Itch score, mean (SD) 39.3 (26.8) 43.5 (21.9) 37.3 (28.6)
Note that the per-protocol and non-per-protocol sets are used for reporting in this table. These two sets correspond to the HPA-axis and non-HPA cohorts,
respectively, with the exception of one patient in the HPA-axis cohort who withdrew after the baseline visit, and is therefore included in the non-per-protocol
set. BSA, body surface area; FAS, full analysis set; HPA, hypothalamic–pituitary–adrenal; PASI, Psoriasis Area and Severity Index; PGA, physician’s global
assessment of disease severity; SD, standard deviation.
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concentration was ≤18 lg/dL at 30 min post-ACTH challenge
at W4 (15.0 lg/dL), values were not normalized at 60 min
(16.0 lg/dL). Further evaluation demonstrated that this
patient had only shown a minimal cortisol response to the
ACTH challenge test at baseline (18.0 and 21.0 lg/dL at 30
and 60 min post-ACTH challenge, respectively) and, as such,
should not have been enrolled into the HPA-axis cohort.
None of the three patients with HPA-axis suppression had
detectable PK analytes.
Pharmacokinetics
Pharmacokinetics data were available for 33 patients in the
HPA-axis cohort. BD was detectable, systemically, for at least
one time-point in 12 patients (36%), with the highest detected
concentration, 480 pg/mL, 1 h after final application of Cal/BD
in W4. A full PK profile (Cmax, AUCall, AUC∞ and T½) was cal-
culable for only one of the 12 patients as just this patient had
detectable BD levels at enough time points. The BD metabolite,
betamethasone 17-propionate, was detectable systemically in six
patients (18%); again, the full PK profile was only calculable in
one patient. None of these patients (with detectable BD or
betamethasone 17-propionate) experienced any AE considered
related to treatment with Cal/BD foam (mild AEs in three
patients). Neither Cal, nor its metabolite MC1080, was detect-
able in any patient samples.
Efficacy
At W4, 71.8% and 75.7% of patients in the overall population
achieved treatment success by PGA on the body and scalp,
respectively (Fig. 4); rates were comparable between patients
aged 12–14 years and 15 to <17 years (data not shown). By
PaGA, treatment success rates were 83.5% and 81.6% on the
body and scalp, respectively (Fig. 5). Rates of treatment success
were lower in the non-HPA cohort than in the HPA-axis cohort
by both PGA (body: 61.4% vs. 93.9%; scalp: 65.7% vs. 97.0%,
respectively) and PaGA (body: 78.6% vs. 93.9%; scalp: 74.3% vs.
97.0%) (Figs 4,5).
Mean PASI scores in the overall population decreased, from
baseline, by 59.1% by W2 (95% CI 54.7%–63.5%) and 82.0% by
W4 (95% CI 78.6%–85.5%). By subgroup analysis, decreases
were generally consistent between cohorts, with mean reductions
of 58.7% and 80.2% in the non-HPA cohort and 59.9% and
85.9% in the HPA-axis cohort by W2 and W4, respectively
(Fig. 6). Mean change in itch intensity from baseline to W4 was
32.5 (95% CI 37.8 to 27.1), according to VAS. Mean
changes of 27.7 and 42.5 were reported in the non-HPA and
HPA-axis cohorts, respectively (Fig. 7).
Discussion
In this phase II, open-label, non-controlled, 4-week study in
adolescents with plaque psoriasis on the body and scalp, Cal/BD
foam was well tolerated. The TEAE profile was comparable with
those previously reported in an adult population.18 In addition,
very few TEAEs were considered related to Cal/BD treatment. It
should be noted that acne (which was considered possibly or
Table 2 Treatment-emergent adverse events at Week 4 in the
safety analysis set (N = 106) by preferred term
Preferred term Number of
patients, n (%)
Upper respiratory tract infection 8 (7.5)
Nasopharyngitis 4 (3.8)
Acne 2 (1.9)
Application site pain 1 (0.9)
Arthralgia 1 (0.9)
Arthropod bite 1 (0.9)
Erythema 1 (0.9)
Folliculitis 1 (0.9)




Oral herpes 1 (0.9)
Pharyngitis 1 (0.9)
Product physical consistency issue 1 (0.9)
Pruritus generalized 1 (0.9)
Psoriasis 1 (0.9)
Pulpitis dental 1 (0.9)
Rhinitis 1 (0.9)
Skin neoplasm excision 1 (0.9)




















































Figure 3 Local safety and tolerability profile of Cal/BD. Presented
as percentage of patients with (a) erythema, (b) dryness, (c) erosion
and (d) oedema at baseline, Week 2 and Week 4. All data shown
are percentages, based on observed cases.
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probably related to treatment) is a particularly common condi-
tion among adolescents more generally.19
The data did not indicate any abnormalities in calcium meta-
bolism; changes were small, transient and not considered clini-
cally relevant. These observations were in line with previous
studies of calcium homoeostasis in patients treated with
Cal/BD.18,20
Slight decreases in serum cortisol were observed in two evalu-
able patients in the HPA-axis cohort at 30 min post-ACTH chal-
lenge, but cortisol values normalized by 60 min post-ACTH
challenge. There was no apparent association between these
decreases and the extent of BSA involvement, PK parameters or
the amount of Cal/BD foam used. As such, it is unlikely these
minor and short-lived decreases are of clinical significance.
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Figure 5 Percentage of patients reporting treatment success by
patient’s global assessment of disease severity at Week 2 and
Week 4 for (a) the body and (b) the scalp. All data are presented as




















































Week 2 Week 4
Figure 6 Mean percentage change in PASI scores from baseline
at Week 2 and Week 4 for the FAS, HPA-axis cohort and non-HPA
cohort. FAS, full analysis set; HPA, hypothalamic–pituitary–






























Figure 7 Mean itch scores at baseline, Week 2 and Week 4 for
the FAS, HPA-axis cohort and non-HPA cohort. FAS, full analysis
set; HPA, hypothalamic–pituitary–adrenal.
Table 3 Shifts in albumin-corrected serum calcium (in the safety analysis set), calcium excretion (in the HPA-axis cohort) and calcium:
creatinine ratio (in the HPA-axis cohort) from baseline to Week 4
Level shifts (baseline–Week 4) Albumin-corrected serum calcium
(n = 106)†
24-h urinary calcium excretion
(n = 34)†
24-h urinary calcium:creatinine ratio
(n = 34)†
Low–Low 3 14 0
Low–Normal 6 3 0
Normal–Low 9 9 0
Normal–Normal 83 6 31
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Figure 4 Percentage of patients with treatment success by PGA
at Week 2 and Week 4 for (a) the body and (b) the scalp. All data
are presented as percentages, based on observed cases. FAS, full
analysis set; HPA, hypothalamic–pituitary–adrenal; PGA, physician
global assessment of disease.
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60 min post-ACTH challenge, which is the standard time used
in clinical practice to search for adrenal insufficiency.17,21
Exploratory efficacy data were encouraging, with PGA- and
PaGA-assessed success rates over 70% and 80%, respectively.
Positive outcomes were also reflected by the PASI and itch scores
[decreases of 82% and 32.5% (measured by VAS), respectively,
from baseline to W4]. Greater improvements in efficacy out-
comes were generally observed in the HPA-axis cohort com-
pared with the non-HPA cohort. Efficacy data in this study are
higher than previous reports of Cal/BD foam in adults [treat-
ment success on the body (by PGA) 71.8% vs. 53.3%],22 despite
similarities in severity of psoriasis (mean PASI/mPASI scores) at
baseline (8.6 vs. 7.5).22 Higher efficacy might partially be
explained by the high compliance rates observed in our study
despite non-adherence to treatment being a particularly com-
mon problem among adolescents23 and patients who receive
topical treatments.24 However, these compliance rates may be a
reflection of the higher patient adherence typically observed in
clinical trials vs. clinical practice.25
Cal/BD metabolites were generally present at very low levels,
and consequently pharmacokinetic parameters were only calcu-
lable in one patient for the BD metabolite betamethasone
17-propionate. Neither Cal, nor its metabolite MC1080, was
detectable in any patients. These data indicated minimal sys-
temic exposure to Cal and BD.
It is important that conclusions drawn in relation to
Cal/BD tolerability are based on the amount of Cal/BD foam
received by the patients in this trial [HPA-axis and non-
HPA cohorts received a mean 47.0 g/week (SD 22.2) and
35.8 g/week (SD 28.0), respectively]. In line with a previous
study that did not report disturbance of calcium homoeostasis
with Cal 45 g/m2 for 8 weeks in children (age 3–14 years;
mean PASI 6.1),26 the present did not suggest disruption of
calcium homoeostasis with 4 weeks’ Cal/BD in adolescents, the
majority of whom had moderate disease at baseline.
The mean weekly amount of Cal/BD used in this study was
below the theoretical permitted amount. The exact reasons are
unknown; however, this may be due to the age of the cohort.
Median age in this study was 14.0 years (maximum 16 years),
meaning most subjects were eligible to receive 60 g/week
Cal/BD. In a maximum-use systemic exposure trial with this
product in 37 adults, the mean weekly amount of Cal/BD used
was 62 g.20 Disease severity may also have contributed: in the
current study, mean PASI score in the overall population was
not indicative of extensive psoriasis [8.6 (SD 4.0)], which may
mean less product was used than supplied.
There were several limitations to this study. The current
study was not designed to determine a maximum tolerated
dose. The open-label design could not exclude the possibility
of investigator bias, while lack of a placebo control group
precluded determination of the true efficacy and safety of
Cal/BD foam in adolescents. Moreover, no patient enrolled
into the HPA-axis cohort had severe psoriasis by PGA. The
duration of the treatment period (as stipulated by the FDA)
was relatively short; 4 weeks’ treatment would be expected to
detect site reactions (e.g. local skin irritation), but may not
suffice to categorically exclude perturbations of calcium
homoeostasis or HPA-axis reported following long-term
exposure to Cal and BD, respectively. Similarly, over the
short treatment period, no plateau was observed with the
efficacy results in either cohort. Therefore, further improve-
ments may occur in both groups (particularly in patients
with more severe disease) with a longer course of treatment.
Further trials, to establish a maximum tolerated dose in ado-
lescent psoriasis patients and to assess safety in adolescent
patients with severe disease by PGA, are warranted.
In conclusion, in this phase 2 trial, fixed-dose combination of
Cal/BD foam was well tolerated in adolescent patients with
mild–moderate body/scalp psoriasis, and exploratory efficacy
data were encouraging.
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